Pharming (PHAR) Gross Margin (2020 - 2026)
Pharming's (PHAR) quarterly Gross Margin came in at 86.97% in Q2 2026, down 8996306191.0% YoY from N/an in Q2 2025, and down 4.25% on a QoQ basis from 90.83% in Q1 2026.
Powered by 
Analysis
Pharming (PHAR) Gross Margin (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Gross Margin data on file, last reported at 86.97% in Q2 2026.
- Quarterly Gross Margin fell 8996306191.0% year-over-year to 86.97% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 86.52% (down 22921981363.0% YoY) and the FY2025 annual result came in at 87.9%, down 19.0% from the prior year.
- Gross Margin declined to 86.97% in Q2 2026, from 90.83% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 179802955665024.62% in Q4 2023 to a low of 0.0% in Q1 2025.
- A 5-year average of 14914355181225.08% and a median of 90.63% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin soared 2000000000 bps — and 2024, when it tumbled 2000000000 bps.
- Tracing PHAR's Gross Margin over 5 years: stood at 92.52% in 2022, then soared by 2000000000 bps to 179802955665024.62% in 2023, then slumped by 51 bps to 88655256723716.38% in 2024, then slumped by 100 bps to 80.19% in 2025, then gained by 8 bps to 86.97% in 2026.
- The last three Gross Margin figures came in at 86.97% (Q2 2026), 90.83% (Q1 2026), and 80.19% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 84.20% |
| 10 | Pharming | 781.07 Mn | 621.57 Mn | 141.47 Mn | 86.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 86.97% |
| Mar 31, 2026 | 90.89% |
| Dec 31, 2025 | 80.19% |
| Sep 30, 2025 | 92.70% |
| Mar 31, 2025 | 89.51% |
| Dec 31, 2024 | 88.66% |
| Sep 30, 2024 | 90.91% |
| Jun 30, 2024 | 152,917,678.81% |
| Mar 31, 2024 | 84.89% |
| Dec 31, 2023 | 91.26% |
| Sep 30, 2023 | 87.56% |
| Jun 30, 2023 | 159.63% |
| Mar 31, 2023 | 90.42% |
| Dec 31, 2022 | 92.52% |
| Sep 30, 2022 | 95.76% |
| Jun 30, 2022 | 92.02% |
| Mar 31, 2022 | 89.48% |
| Dec 31, 2021 | 89.91% |
| Sep 30, 2021 | 88.64% |
| Jun 30, 2021 | 90.76% |